GLP-2 (TRZ) 100mg Review

Tirzepatide occupies a structurally and pharmacologically distinct position among incretin-based research peptides. Unlike single-receptor GLP-1 agonists, tirzepatide is an engineered 39-amino-acid acylated peptide that simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). That dual agonism produces a metabolic profile that has attracted substantial peer-reviewed attention across glycemic control, body-weight regulation, and cardiovascular risk endpoints.

The 100 mg vial format sold by Apollo Peptide Sciences under the catalog designation GLP-2 (TRZ) is intended for bulk laboratory use, offering researchers a cost-effective route to larger-volume in-vitro work, cell-based assay panels, and multi-arm rodent studies. At $360.00, the per-milligram cost compares favorably with smaller-format vials when research protocols require repeated dosing across extended timelines.

This review evaluates the compound against published pharmacology, examines what a credible certificate of analysis (CoA) should report, and places the product in the context of competing incretin research peptides available from reputable suppliers. All dose figures referenced throughout are drawn from published preclinical and clinical literature and are presented as literature-reported research parameters, not recommendations for human use.

Editor's Verdict

The GLP-2 (TRZ) 100mg vial earns a strong editorial recommendation for metabolic research applications where dual GLP-1R and GIPR agonism is the experimental variable. The primary caveats are standard to any research-grade peptide: independent CoA verification is non-negotiable, and researchers should establish internal positive controls using characterized reference standards before committing bulk material to endpoint assays.

Specifications

Researchers planning multi-week rodent studies should note that the lyophilized powder is stable for at least 24 months at -20°C in a desiccated environment, consistent with published handling recommendations for acylated GLP-1-class peptides. ^[1] Once reconstituted, repeated freeze-thaw cycles degrade peptide integrity; single-use aliquots stored at -80°C are the standard laboratory practice. See the reconstitution guide for detailed solvent selection and sterile technique.

What It Is, Chemistry, Origin, and Sequence

Structural origins

Tirzepatide was designed by Eli Lilly chemists as a synthetic, dual-acting incretin mimetic. Its amino-acid backbone shares structural homology with the natural glucose-dependent insulinotropic polypeptide (GIP), while several strategic substitutions confer meaningful GLP-1R binding affinity that the native GIP molecule lacks. The result is a single peptide chain that functions as an agonist at both receptors rather than a mixture of two separate agonists, which has pharmacokinetic and signaling implications discussed in later sections. ^[2]

The sequence is 39 residues long. Position 2 carries an Aib (alpha-aminoisobutyric acid) substitution in place of the alanine found in native GIP; this change blocks DPP-4 cleavage at the N-terminus, which is the primary degradation pathway that limits circulating half-life for unmodified incretin peptides. ^[3] Several additional Aib insertions along the backbone stabilize the alpha-helical secondary structure that is required for receptor engagement at both GLP-1R and GIPR. These structural modifications collectively distinguish tirzepatide from earlier-generation compounds such as exendin-4 (exenatide) or liraglutide, which act exclusively at GLP-1R.

Acylation chemistry

The fatty-acid appendage is critical to tirzepatide's extended half-life. A C18 fatty diacid is attached at Lys34 through a hydrophilic linker composed of a gamma-glutamic acid spacer and two mini-polyethylene glycol (PEG) units. This architecture mirrors the acylation strategy used for semaglutide (C18 fatty diacid at Lys26/34), though the exact linker chemistry differs. The acyl group facilitates non-covalent binding to serum albumin, which shields the peptide from renal filtration and proteolytic degradation, extending the half-life to approximately five days in humans. ^[4] In rodent models the half-life is considerably shorter (estimated 2-6 hours for subcutaneous administration depending on the study), which has implications for translating literature-reported animal-equivalent doses to experimental design.

Physicochemical properties

Tirzepatide is a white to off-white lyophilized solid. It is freely soluble in aqueous buffers at physiological pH and moderately soluble in dimethyl sulfoxide (DMSO), though DMSO is not recommended as a primary solvent for in-vivo rodent work due to carrier effects at the volumes required. The isoelectric point is reported in the mildly acidic range (approximately pH 5.5-6.0), consistent with the amino-acid composition and fatty-acid modifications. Published PubChem records assign CAS number 2023788-19-2 and report a molecular weight of approximately 4813 Da, though the precise value depends on the salt form and hydration state of the lyophilized material. ^[5]

Relationship to other incretin peptides

GIP itself is a 42-amino-acid peptide secreted by K-cells of the proximal small intestine in response to fat and carbohydrate ingestion. Its cognate receptor (GIPR) is expressed in pancreatic beta cells, adipocytes, brain regions governing energy homeostasis, and bone. GLP-1 is a 30/31-amino-acid peptide secreted by intestinal L-cells; its receptor (GLP-1R) is expressed in pancreatic beta and alpha cells, the cardiovascular system, kidney, and the central nervous system. ^[6] By designing a single scaffold that engages both systems, Lilly's chemists created a molecule whose pharmacology is qualitatively different from either native hormone or from mono-specific agonists. The research community continues to delineate which phenotypic effects arise from each receptor arm versus from the combined signal.

Mechanism of Action

GLP-1 receptor engagement

Tirzepatide binds GLP-1R with a potency approximately 5-fold lower than that of native GLP-1 on a molar basis in in-vitro assay systems, but this apparent weakness is offset by the extended half-life and by allosteric effects that may differ from those of full agonists. ^[3] GLP-1R is a class B G-protein-coupled receptor (GPCR). Ligand binding triggers coupling primarily to the Gs alpha subunit, elevating intracellular cyclic AMP (cAMP). In pancreatic beta cells, elevated cAMP activates protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac2), which potentiates glucose-stimulated insulin secretion (GSIS) in a glucose-dependent manner. The glucose dependency is mechanistically important: below fasting glucose thresholds, GLP-1R agonism produces minimal insulin secretion, which constrains hypoglycemia risk compared with sulfonylureas. ^[7]

Beyond the pancreas, GLP-1R signaling in hypothalamic and brainstem circuits (arcuate nucleus, nucleus tractus solitarius, area postrema) reduces food intake by decreasing appetite and increasing satiety signals. Gastric emptying is slowed via vagal pathways, which blunts postprandial glucose excursions. Cardiac GLP-1R activation contributes to favorable effects on heart rate (a mild chronotropic increase) and myocardial protection in ischemia models. ^[8]

GIP receptor engagement

Tirzepatide binds GIPR with potency roughly equivalent to native GIP, making it a full agonist at this receptor. GIPR, also a class B GPCR, couples to Gs and raises cAMP in target cells. In beta cells, the GIPR-mediated cAMP increase synergizes with GLP-1R signaling to amplify insulin secretion beyond what either receptor achieves alone. This additivity at the level of cAMP has been proposed as a primary driver of tirzepatide's superior glycemic efficacy relative to selective GLP-1R agonists in head-to-head trials. ^[9]

In adipose tissue, GIPR agonism has historically been linked to lipogenesis and fat storage in high-fat feeding contexts, which raised early concerns that GIPR activation might counteract GLP-1-mediated weight loss. The published data from tirzepatide trials challenged this framing: body weight and fat mass reductions observed in clinical studies exceeded those attributable to GLP-1R agonism alone. Mechanistic work in rodent models suggests that GIPR agonism in adipocytes may actually reduce adipose inflammation and improve lipid handling under conditions of dual-receptor co-activation, though the precise adipose biology remains an active research question. ^[10]

Central nervous system signaling

Both GLP-1R and GIPR are expressed in circumventricular organs and hypothalamic nuclei that regulate feeding behavior, energy expenditure, and reward. ^[6] Intracerebroventricular injection studies in rodents demonstrate that central GLP-1R activation reduces food intake independently of peripheral glucoregulation, and GIPR agonism centrally appears to contribute to energy expenditure regulation. The relative contribution of central versus peripheral receptor activation to the whole-body phenotype observed with tirzepatide is not fully resolved; studies using receptor-specific knockout mice have begun to attribute distinct portions of the body-weight effect to central GIPR signaling. ^[11]

Downstream signaling and transcriptional effects

The elevated cAMP generated by Gs-coupled receptor activation at both GLP-1R and GIPR drives multiple downstream transcriptional programs. In beta cells, PKA-mediated phosphorylation of CREB promotes expression of genes involved in insulin biosynthesis and beta-cell survival, including Pdx1, MafA, and Nkx6.1. In hepatocytes, GLP-1R signaling modulates FoxO1 activity, reducing gluconeogenic gene expression (PEPCK, G6Pase) and thereby contributing to fasting glucose reduction. ^[12] In skeletal muscle and adipose tissue, both receptors converge on pathways that regulate glucose transporter 4 (GLUT4) translocation and lipid turnover. The net transcriptional effect is a coordinated shift toward improved substrate utilization across multiple metabolic tissues.

Biased agonism considerations

There is evidence from in-vitro studies that tirzepatide behaves as a biased agonist at GLP-1R, preferentially driving Gs-cAMP signaling over beta-arrestin recruitment relative to native GLP-1. ^[3] Beta-arrestin recruitment mediates receptor internalization and desensitization; reduced arrestin recruitment could theoretically sustain receptor surface expression and prolong the cellular response per activation event. Whether this bias translates to meaningful differences in receptor desensitization during chronic administration is an open research question with direct relevance to long-term in-vivo study design.

What the Research Says

SURPASS-2: Head-to-head against semaglutide 1 mg

The SURPASS-2 trial, published by Frias and colleagues in the New England Journal of Medicine in 2021, was a 40-week, open-label, randomized controlled trial comparing tirzepatide (5 mg, 10 mg, and 15 mg weekly) against semaglutide 1 mg weekly in adults with type 2 diabetes inadequately controlled on metformin. ^[9] The primary endpoint was change in HbA1c from baseline. The trial enrolled 1,879 participants across 128 sites in eight countries.

All three tirzepatide doses produced statistically superior HbA1c reductions compared with semaglutide 1 mg. The 15 mg tirzepatide arm achieved a mean HbA1c reduction of 2.46 percentage points versus 1.86 points for semaglutide (difference -0.60 percentage points; 95% CI -0.76 to -0.45; P less than 0.001). Body weight reductions were similarly differentiated: tirzepatide 15 mg produced a mean reduction of 12.4 kg versus 6.2 kg for semaglutide 1 mg. These data positioned dual GLP-1R/GIPR agonism as producing qualitatively superior metabolic outcomes relative to selective GLP-1R agonism at comparable weekly dosing intervals.

The trial's limitations are relevant for research design. It was open-label rather than double-blind, introducing potential for differential reporting of subjective endpoints. The semaglutide comparator was the 1 mg subcutaneous dose rather than the higher 2 mg dose approved in later years, which may understate semaglutide's true competitive ceiling. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common treatment-related events and occurred at broadly similar rates across groups, suggesting the GI profile is a class effect of incretin agonism rather than specific to dual-receptor engagement.

For laboratory researchers, SURPASS-2 provides the key dose-response coordinates in a human population: the 5-to-15 mg weekly range, titrated incrementally from 2.5 mg, is the reference frame for allometric scaling calculations when designing rodent studies. Published rodent work has used subcutaneous doses ranging from 0.03 to 1.0 nmol/kg (daily or three times weekly) to model this clinical range, recognizing that the shorter rodent half-life requires more frequent administration to approximate steady-state exposures. ^[13]

SURMOUNT-1: Weight loss in adults without diabetes

Jastreboff and colleagues published the SURMOUNT-1 results in the New England Journal of Medicine in 2022, representing the first large-scale trial examining tirzepatide specifically in adults with obesity or overweight (BMI at least 30, or at least 27 with at least one weight-related comorbidity) but without type 2 diabetes. ^[14] The trial enrolled 2,539 participants and ran for 72 weeks, with participants receiving weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo after a 4-week titration period.

The primary weight-loss endpoints were striking. Participants receiving 15 mg tirzepatide lost a mean of 22.5% of body weight versus 2.4% for placebo, a difference of 20.1 percentage points (95% CI -21.0 to -19.2; P less than 0.001). The 10 mg dose produced a mean 21.4% reduction; the 5 mg dose, 16.0%. By comparison, published meta-analyses of semaglutide 2.4 mg (the obesity-approved dose) report mean weight reductions of approximately 14.9% at 68 weeks, placing the highest tirzepatide doses numerically ahead.

Mechanistically, SURMOUNT-1 is valuable because it decoupled the weight-loss effect from confounding by glycemic improvement. In a normoglycemic population, the weight reduction can be attributed more directly to the appetite, satiety, and energy-expenditure pathways rather than to improved insulin sensitivity secondarily reducing fat deposition. The study also reported significant reductions in waist circumference, visceral adipose tissue by imaging substudy, and improvements in cardiometabolic biomarkers (blood pressure, lipids, C-reactive protein), consistent with tirzepatide acting across multiple obesity-adjacent pathways rather than solely through caloric restriction. ^[14]

Limitations include the predominantly White, female study population (67.5% female, primarily North American and European sites), which may limit generalizability across genetic backgrounds known to differ in incretin response. The 72-week data also does not address weight regain after discontinuation, which was characterized in a subsequent withdrawal extension study.

Preclinical mechanistic work: Dual agonism in rodent obesity models

Several rodent studies preceded the large clinical trials and provide mechanistic context that purely clinical data cannot. Coskun and colleagues (2022) published a detailed characterization of tirzepatide in high-fat-diet (HFD) obese mice, demonstrating that tirzepatide outperformed selective GLP-1R agonists on body weight, fat mass, and energy expenditure endpoints. ^[10] Using chronic subcutaneous dosing in diet-induced obese (DIO) C57BL/6J mice, the study found that tirzepatide at 0.1 nmol/kg three times weekly reduced body weight by approximately 25% over 12 weeks versus 15% for a matched GLP-1R-selective comparator peptide.

Critically, the Coskun study employed indirect calorimetry to demonstrate an increase in energy expenditure in tirzepatide-treated mice that was not seen to the same degree in the GLP-1R-selective group, suggesting that GIPR activation contributes to the metabolic rate component of weight loss rather than exclusively suppressing intake. This finding aligns with the SURMOUNT-1 observation that tirzepatide produces weight losses exceeding predictions based on caloric restriction data alone.

The study also quantified liver triglyceride content by biochemical extraction and histological scoring, finding significant reductions in hepatic steatosis grade in tirzepatide-treated animals. This is mechanistically relevant because GIPR is expressed in hepatocytes and can reduce lipid synthetic gene expression (FASN, SREBP-1c) through cAMP-mediated pathways independently of insulin. The finding has since been replicated in human biopsy-based substudies of clinical trials, supporting translational validity of the DIO mouse model for this endpoint.

Limitations of the Coskun rodent work include the reliance on a single inbred mouse strain, which captures a specific genetic background for obesity susceptibility, and the use of twice or three-times-weekly dosing rather than once-weekly, which researchers should account for when designing analogous studies given the pharmacokinetic differences between species.

Pharmacological context: Receptor co-agonism and the incretin effect

Understanding tirzepatide's mechanism requires situating it within the broader incretin biology literature. The incretin effect, first described by Mcintyre and colleagues in 1964 and later elaborated by Holst and Drucker, refers to the observation that oral glucose produces 2-3 times more insulin secretion than the same glucose load administered intravenously, attributable to GIP and GLP-1 released from the gut. ^[15] In type 2 diabetes, the incretin effect is markedly impaired: GLP-1 secretion is modestly reduced, but more critically the beta-cell response to GIP becomes severely blunted, such that infused GIP produces minimal insulin secretion in diabetic subjects. This paradox initially made GIPR a less attractive drug target.

Later work by Nauck, Meier, and colleagues demonstrated that the impaired GIPR responsiveness in type 2 diabetes is partially reversible with improved glycemic control, raising the hypothesis that a compound capable of restoring beta-cell sensitivity to GIP simultaneously with improving glucose control could amplify its own efficacy over time. Tirzepatide's clinical HbA1c data are consistent with this model: the magnitude of glycemic benefit exceeds what pharmacokinetic differences alone would predict compared with semaglutide, implying a genuine pharmacodynamic synergy between the two receptor arms. ^[15]

The GIPR-in-adipose controversy is a persistent open question in this field. Historical in-vitro and animal data showed GIPR agonism promoting adipogenesis and fat storage, which led some investigators to predict that GIPR activation would be metabolically harmful. Tirzepatide's clinical data directly contradicted this prediction, prompting a reexamination of adipose GIPR biology under conditions of co-activation with GLP-1R. Current hypotheses include the possibility that the physiological context (energy surplus vs. energy deficit), the presence of simultaneous GLP-1R signaling, or differences in adipose GIPR expression between obese and lean states fundamentally alter the direction of GIPR's adipose effect. ^[10]

SURPASS-CVOT: Cardiovascular outcomes

The SURPASS-CVOT trial, reported by Bhatt and colleagues in 2023, examined cardiovascular outcomes in adults with type 2 diabetes and established cardiovascular disease, comparing tirzepatide against dulaglutide, a selective GLP-1R agonist, over a median follow-up of approximately 2.4 years. ^[16] The primary composite endpoint (major adverse cardiovascular events, MACE) showed a non-inferiority result for tirzepatide versus dulaglutide, with a hazard ratio of 0.85 (95% CI 0.71 to 1.02), meeting the pre-specified non-inferiority margin.

For research purposes, this trial is instructive in two ways. First, it establishes that the cardiovascular safety profile of dual GLP-1R/GIPR agonism is broadly comparable to established GLP-1R-selective therapy in a high-risk cardiovascular population, removing a major theoretical concern about GIPR-mediated cardiac effects at pharmacological doses. Second, the numerically lower MACE rate in the tirzepatide arm (though not reaching superiority significance) justifies continued investigation of the cardiovascular biology of dual incretin agonism, particularly in atherosclerosis, cardiac remodeling, and heart failure models.

The trial enrolled 1,127 participants, a relatively small CVOT cohort compared with landmark trials like LEADER (liraglutide, n=9,340) or SUSTAIN-6 (semaglutide, n=3,297), which limits statistical power for subgroup analyses. The use of an active comparator (dulaglutide) rather than placebo means the trial cannot establish absolute cardiovascular benefit against background standard of care. Researchers designing cardiovascular mechanistic studies with tirzepatide should use this trial as a safety reference frame but rely on in-vitro cardiomyocyte and ex-vivo vascular work for mechanistic endpoint validation.

Pharmacokinetics

The approximately 5-day half-life in humans arises from three protective mechanisms acting in concert: DPP-4 resistance conferred by the N-terminal Aib substitution, albumin binding mediated by the C18 fatty diacid chain, and alpha-helical stabilization reducing conformational flexibility that would otherwise expose the backbone to endopeptidases. ^[4] This pharmacokinetic architecture means that once-weekly human dosing maintains plasma concentrations within a relatively narrow peak-to-trough ratio, which is mechanistically important for sustained receptor engagement.

In rodent models, the much shorter half-life means that a once-weekly dosing schedule would produce a very different receptor occupancy profile from that seen clinically. Published preclinical studies have used subcutaneous dosing every 72 hours (three times weekly) or daily as approaches to approximate more continuous receptor engagement. ^[13] Researchers designing rodent studies should refer to published pharmacokinetic modeling data and consider plasma collection time points to confirm exposure before interpreting pharmacodynamic outcomes.

The volume of distribution of approximately 10 L in humans suggests that tirzepatide distributes primarily within the vascular and interstitial space rather than penetrating deeply into intracellular compartments. This is consistent with its molecular size (~4813 Da), which precludes passive transmembrane diffusion; tissue uptake depends on receptor-mediated endocytosis and transcytosis. Brain penetration is limited under normal blood-brain barrier conditions, though circumventricular organs lack tight junctions and are accessible to circulating tirzepatide, which is the proposed route by which the peptide accesses hypothalamic and brainstem circuits. ^[11]

Purity and Verification

What a credible CoA should contain

Research-grade tirzepatide should be accompanied by a certificate of analysis that reports a minimum set of analytical parameters. Purity by reversed-phase high-performance liquid chromatography (RP-HPLC) should be at least 98% (area percentage at 214 nm or 220 nm), with the main peak identified by retention time against a reference standard. Any single impurity peak should be below 0.5% by area, and the CoA should explicitly state the column chemistry, gradient conditions, and detection wavelength used.

Mass confirmation by electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) should report the observed monoisotopic or average mass within 0.5 Da of the theoretical value for tirzepatide free base or the stated salt form. The CoA should list the molecular formula and calculated mass for reference. Given tirzepatide's size and acylation complexity, multiply-charged ion series (z = +4 to +8) are typically observed in ESI-MS and should be reported.

Peptide content (by quantitative amino-acid analysis or UV absorbance with an established extinction coefficient) matters for accurate dosing calculations in research protocols. A nominal 100 mg vial of 95% pure peptide contains only 95 mg of active compound; if peptide content is not corrected for, dose-response interpretations will be inaccurate. Endotoxin testing by limulus amebocyte lysate (LAL) assay should be reported with a result below 1 EU/mg, and ideally below 0.1 EU/mg for in-vivo work where pyrogenic contamination would confound inflammatory endpoints.

Independent verification approach

Relying solely on vendor-supplied CoA data introduces confirmation bias; the most rigorous research programs verify a subset of vials by independent analysis. The recommended approach is to submit a small aliquot (typically 0.5-1 mg) to a third-party analytical laboratory with documented LC-MS capabilities for peptide characterization.

A practical workflow is to first confirm identity by full-scan ESI-MS, then quantify purity by RP-HPLC with UV detection, and finally check for sequence truncations or insertions using tandem MS fragmentation (MS/MS with b- and y-ion series assignment). Truncated sequences that differ by one or two amino acids can co-elute with the target peptide by standard HPLC and are only resolved by mass-directed methods.

For endotoxin, independent LAL testing costs approximately $50-100 per sample and is particularly valuable before first-use in inflammatory or immunological research models where lipopolysaccharide contamination would be a direct confound. Some academic core facilities offer this service at reduced cost for institutional users. Researchers at institutions with analytical chemistry cores may be able to arrange NMR-based amino-acid profiling as an orthogonal identity check, though this is less common for peptides of this size.

See the supplier evaluation guide for a structured approach to vendor selection and CoA interpretation, including a checklist of disqualifying CoA deficiencies.

Dosage and Reconstitution

Reconstitution

Lyophilized tirzepatide powder should be reconstituted by slowly adding sterile diluent to the vial wall rather than directly onto the powder cake to avoid foaming and peptide denaturation. For a 100 mg vial, the choice of final concentration depends on the planned research protocol and the injection volumes appropriate for the model system.

Common reconstitution concentrations in published rodent studies range from 0.1 mg/mL to 1.0 mg/mL in sterile 0.9% sodium chloride or sterile phosphate-buffered saline (PBS) at pH 7.4. ^[13] For in-vitro work (cell-based receptor activation assays, cAMP accumulation measurements), DMSO-based stock solutions at 10 mM are common; these are diluted at least 1:1000 into aqueous assay buffer to keep the final DMSO concentration below 0.1%, which is the standard threshold for avoiding cytotoxicity or membrane disruption artifacts.

For multi-week rodent studies using the 100 mg bulk vial, a practical approach is to reconstitute a 10 mg/mL master stock in sterile water, filter-sterilize through a 0.22 µm membrane, aliquot into 1 mg aliquots in sterile low-binding tubes, and store at -80°C. Working aliquots can be thawed at 4°C and diluted to the protocol-specified concentration immediately before use. This minimizes freeze-thaw degradation and maintains sterility.

Worked numerical examples

Example 1: Rodent study at 0.1 nmol/kg (3x weekly subcutaneous)

Published DIO mouse work uses 0.1 nmol/kg tirzepatide three times weekly as a moderate-dose condition. ^[10] Tirzepatide molecular weight is approximately 4813 Da. For a 25 g mouse (0.025 kg): required dose = 0.1 nmol/kg x 0.025 kg = 0.0025 nmol = 0.0025 x 10^-9 mol. Converting to mass: 0.0025 x 10^-9 mol x 4813 g/mol = 12.03 x 10^-9 g = 12.0 ng per injection. At a working stock of 0.01 mg/mL (10 µg/mL), this requires 1.2 µL per injection. Subcutaneous volumes in mice are typically 50-200 µL, so diluting to 0.24 µg/mL and delivering 50 µL would be more practical for accurate pipetting.

Example 2: Higher-dose rodent protocol at 1.0 nmol/kg

At 1.0 nmol/kg for a 25 g mouse: 0.025 nmol = 0.025 x 4813 x 10^-9 g = 120.3 ng per injection. At 0.24 µg/mL working stock, 50 µL delivers 12 ng, so for 120 ng the stock concentration should be approximately 2.4 µg/mL. Working backward: from a 10 mg/mL master stock, a 1:4166 dilution in PBS gives 2.4 µg/mL. Two-step serial dilution (1:100 to 100 µg/mL, then 1:41.7 to 2.4 µg/mL) is manageable on the bench.

Example 3: Cell-based cAMP assay

For a GLP-1R or GIPR cAMP accumulation assay, EC50 values for tirzepatide at GLP-1R are reported in the range of 10-100 pM depending on cell line and assay format. ^[3] A typical concentration-response curve spans six to eight points from 0.001 nM to 100 nM (final in-well concentration). Starting from a 1 mM DMSO stock prepared by dissolving 4.813 µg in 1 µL DMSO (noting that 1 mg dissolved in 207.8 µL DMSO gives approximately 1 mM): dilute 1:1000 into PBS to give 1 µM aqueous intermediate; then prepare serial 1:10 dilutions to cover the full concentration range, ensuring final DMSO does not exceed 0.1%.

For detailed reconstitution technique including sterile filtration, solvent compatibility, and stability testing, see the peptide reconstitution guide. For dosage conversion calculations and allometric scaling between species, see the dosage calculation guide.

Side Effects and Safety

Gastrointestinal effects

The most consistently reported adverse events in clinical tirzepatide trials are gastrointestinal: nausea, vomiting, diarrhea, constipation, and decreased appetite. ^[9] In SURPASS-2, nausea occurred in 17-22% of tirzepatide recipients versus 18% of semaglutide recipients, and vomiting in 6-10% versus 8%, indicating that GI tolerability is broadly comparable across dual and selective GLP-1R agonists and is likely a class effect mediated by GLP-1R activation in the gut and brainstem. In clinical use, a titration protocol (starting at 2.5 mg weekly with dose escalation every 4 weeks) substantially reduces GI event rates; this titration logic is also used in rodent studies employing escalating-dose designs.

Hypoglycemia

Tirzepatide's glucose-dependent mechanism of action renders hypoglycemia rare as a direct compound effect. In SURPASS-2, severe hypoglycemia occurred in less than 1% of participants not also receiving insulin or sulfonylurea. The glucose-dependent insulin secretion profile of GLP-1R agonism means insulin release ceases when plasma glucose falls below approximately 4 mmol/L. Researchers using rodent fasting or glucose clamp protocols alongside tirzepatide administration should account for this mechanism to avoid misinterpreting glucose curves.

Pancreatic and thyroid considerations

Preclinical rodent data with GLP-1R agonists have shown increased rates of C-cell thyroid hyperplasia and carcinoma in rats at suprapharmacological doses, owing to high GLP-1R expression in rodent thyroid C-cells. This finding does not directly translate to humans (human thyroid C-cells express minimal GLP-1R) but is relevant to rodent study design. ^[17] Researchers conducting long-term rodent studies with tirzepatide should include thyroid histopathology in their endpoint panels if the study duration exceeds 12 weeks, consistent with standard regulatory toxicology guidance.

Acute pancreatitis signals have been observed at the population level with GLP-1R agonist class drugs, though causality remains debated. In tirzepatide clinical trials, pancreatitis rates were numerically similar to or below comparator arms. For in-vitro acinar cell research or studies using pancreatitis models, tirzepatide should be treated as a potential confound variable requiring dedicated controls.

Cardiovascular effects

The mild chronotropic effect of GLP-1R agonism (mean heart rate increase of 2-4 bpm in clinical trials) is a class effect of incretin agonists and has been attributed to direct cardiac GLP-1R activation and reduced baroreceptor sensitivity. ^[8] In rodent telemetry studies, higher-dose tirzepatide produces a detectable heart rate increase that researchers should record as a pharmacodynamic marker rather than a toxicity signal.

Considerations specific to research-peptide format

Research-grade tirzepatide is not manufactured under pharmaceutical GMP conditions and may contain levels of impurities, endotoxin, or residual solvents that would be unacceptable in a clinical product. For in-vivo rodent work, endotoxin contamination at levels above the in-vivo pyrogen threshold (approximately 0.1 EU/kg for rodents) can trigger systemic inflammatory responses that confound metabolic, inflammatory, and behavioral endpoints. This is a critical quality control consideration that goes beyond CoA review to independent LAL testing as described in the Purity section.

How It Compares

Tirzepatide occupies a distinct niche within the incretin research peptide landscape. Against selective GLP-1R agonists (semaglutide, liraglutide, exenatide), tirzepatide's key differentiator is dual receptor engagement, which provides both a superior pharmacodynamic tool for studying GLP-1R/GIPR interaction and a larger body weight effect that is mechanistically informative for energy homeostasis research. Against semaglutide in particular, the additional GIPR component allows researchers to probe GIPR-dependent signaling by comparing tirzepatide to semaglutide at receptor-matched conditions, an approach used in several mechanistic publications. ^[9]

Against the emerging triple agonist retatrutide (GLP-1R + GIPR + glucagon receptor), tirzepatide lacks the glucagon receptor (GCGR) component. GCGR co-activation adds a hepatic gluconeogenesis-suppression mechanism and a distinct energy expenditure component; for researchers specifically interested in comparing dual versus triple incretin agonism, tirzepatide serves as the dual-agonist control in a three-way experimental design.

For researchers focused purely on GIPR biology, comparing tirzepatide against GIP (1-42) or selective GIPR agonist peptides in parallel is the standard approach to attribute phenotypic effects to the GIPR arm specifically. Native GIP has a very short half-life and is rarely practical for multi-week dosing studies without protective modifications, making synthetic GIP analogs or the tirzepatide/GLP-1R agonist subtraction approach the more common experimental strategies.

Where to Buy

Apollo Peptide Sciences supplies GLP-2 (TRZ) under catalog designation glp-2-trz-100mg. See the full product review and affiliate-linked vendor page for current pricing, availability, and any active batch CoA information.

Before committing to any vendor for a large-vial purchase, review the structured evaluation criteria in our supplier guide, which covers CoA interpretation, vendor red flags, third-party verification resources, and price comparison across the incretin peptide category. A $360.00 price point for 100 mg of tirzepatide is within the competitive range for research-grade material from established peptide vendors as of mid-2026, though pricing in this category changes with synthesis scale and raw-material costs.

For researchers who need smaller quantities for pilot experiments before committing to a bulk purchase, the 5 mg and 10 mg vial formats are available in the same incretin category. See the GLP/incretin research peptide index for a full category overview and comparative rankings.

Open Research Questions

The dual GLP-1R/GIPR pharmacology of tirzepatide raises several contested or incompletely resolved research questions that represent active areas of investigation in the published literature.

GIPR agonism versus GIPR antagonism as a weight-loss strategy: A paradox in the incretin field is that GIPR antagonism in rodents also produces weight loss, suggesting that both activation and blockade of GIPR can reduce adiposity depending on context. ^[10] The resolution of this paradox requires understanding the cell-type-specific and physiological-state-specific directionality of GIPR signaling. Tirzepatide, as a full GIPR agonist, provides one experimental probe; selective GIPR antagonist peptides provide the complementary tool. Studies comparing the two approaches in the same model system are ongoing.

Relative contribution of GLP-1R vs. GIPR to weight loss in tirzepatide-treated subjects: Clinical trial subtraction studies (comparing tirzepatide against equipotent GLP-1R-selective doses) and receptor-specific knockout rodent work have begun to attribute approximately 50-60% of tirzepatide's extra weight loss versus semaglutide to the GIPR component. However, these estimates depend on assumptions about receptor occupancy matching that are difficult to verify experimentally, and the central versus peripheral contributions of each receptor arm remain to be fully partitioned. ^[11]

Long-term beta-cell effects: Whether chronic dual incretin agonism preserves, expands, or eventually desensitizes beta-cell mass is a mechanistically important open question. Short-term clinical data suggest beta-cell function markers (HOMA-B, C-peptide response) improve with tirzepatide treatment, consistent with reduced glucotoxicity. Multi-year data with pancreatic imaging endpoints are not yet available.

Non-alcoholic steatohepatitis (NASH) biology: Several clinical trials are ongoing to characterize tirzepatide's effects on NASH and liver fibrosis. Preclinical data are promising (hepatic triglyceride reduction, fibrosis marker suppression in DIO models), but histological biopsy-validated efficacy in human NASH trials is not yet fully published. This represents a significant near-term data gap.

Central GIPR pharmacology: Brain-penetrant GIPR agonist and antagonist tools are being developed to dissect the central versus peripheral contributions of GIPR signaling to energy homeostasis. Current tirzepatide mechanistic studies in the CNS are largely correlative; causal experiments using conditional knockout and viral vector approaches are underway.

FAQ